Celltrion’s ‘Truxima’ reaches 30% market share in Europe only in 3 months of launch
‘Truxima,’ an antibody biosimilar launched by Celltrion Healthcare for the 2nd time in Europe, seems to rapidly grow in the European market.
Celltrion Healthcare announced on the 1st that ‘Truxima,’ an antibody biosimilar developed by Celltrion for the treatment of blood cancer, exceeded a 30% m...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.